Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Thoracic 1

Conditions

Respiratory Tract Diseases 1Neoplasms 1Meningeal Carcinomatosis 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

pembrolizumab 610Carboplatin 375Paclitaxel 283Cisplatin 268Gemcitabine 256Pemetrexed 194Bevacizumab 191Nivolumab 190Docetaxel 190Injections 169Cyclophosphamide 148atezolizumab 138Capecitabine 134Fluorouracil 133Oxaliplatin 132Dexamethasone 129Fulvestrant 115durvalumab 114130-nm albumin-bound paclitaxel 111fludarabine 102Cetuximab 101Leucovorin 97Rituximab 96venetoclax 90Lenalidomide 84Prednisone 79enzalutamide 78Azacitidine 76Irinotecan 74Ipilimumab 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × AZD3759 × 1 year × Clear all
NCT07361705 2026-01-23

Zorifertinib With Osimertinib for NSCLC With Meningeal Progression

Alpha Biopharma (Jiangsu) Co., Ltd.

Phase 1 Not yet recruiting
42 enrolled
CNS

Meningeal Carcinomatosis

NCT03653546 2025-09-10

BM

Alpha Biopharma (Jiangsu) Co., Ltd.

Phase 2/3 Completed
492 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡